|
|
|
|
Study in Nature: MicroRNAs hold promise for treating diseases in blood vessels
A newly discovered mechanism controls whether muscle cells in blood vessels hasten the development of both atherosclerosis and Alzheimer's disease, according to an article published online today in the journal Nature.The study was led by...
|
|
|
Study in Nature: MicroRNAs hold promise for treating diseases in blood vessels
A newly discovered mechanism controls whether muscle cells in blood vessels hasten the development of both atherosclerosis and Alzheimer's disease, according to an article published online today in the journal Nature.The study was led by...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL)...
|
|
|
Childhood obesity in Australia remains a widespread health concern that warrants population-wide prevention pr
To the Editor: Gill and colleagues point out that obesity trends have climbed over decades, and state that 6%8% of Australian school children are affected.1 While this is a substantial burden of over a quarter of a million children, we also...
|
|
|
FDA Approves Multaq To Treat Heart Rhythm Disorder
The U.S.Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to...
|
|
|
FDA Approves Multaq to Treat Heart Rhythm Disorder
The U.S.Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to...
|
|
|
FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Multaq approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - U.S commercial launch planned for the summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced...
|
|
|
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Main Category: / CardiologyAlso Included In: Article Date: 03 Jul 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients...
|
|
|
Sleep Duration Associated With Variations In Levels Of Inflammatory Markers In Women
A study in the July 1 issue of the journal SLEEP demonstrates that levels of inflammatory markers varied significantly with self-reported sleep duration in women but not men.The study found that both interleukin-6 (IL-6) and high...
|
|
|
Seek Out Credentials Before Choosing A Physician - Is Your Cardiologist Board Certified In Cardiovascular Dise
Credentials Before Choosing A Physician - Is Your Cardiologist Board Certified In Disease?Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and...
|
|
|
Multaq (dronedarone'Sanofi-aventis) approved for treating heart rhythm disorder
FDA NEWS RELEASE Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov The U.S.Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial...
|
|
|
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Cardiovascular / Cardiology News Main Category: Cardiovascular / Cardiology Also Included In: Regulatory Affairs / Drug Approvals; Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry email to a friend printer...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 PARIS, July 2 (HSMN NewsFeed) -- Sanofi-aventis ...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and Drug...
|
|
|
Master Stem Cell for Human Heart Identified
WEDNESDAY, July 1 (HealthDay News) -- For the first time, researchers have identified a single 'master' stem cell in humans that is capable of differentiating into all three major cell types that make up the human heart.'This is a very...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and Drug...
|
|
|
Master Stem Cell for Human Heart Identified
WEDNESDAY, July 1 (HealthDay News) -- For the first time, researchers have identified a single 'master' stem cell in humans that is capable of differentiating into all three major cell types that make up the human heart.'This is a very...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation ...
|
|
|
FDA approves dronedarone for atrial fibrillation
Silver Spring, MD - The US Food and Drug Administration (FDA) has approved dronedarone (Multaq, Sanofi-Aventis) to reduce the risk of cardiovascular hospitalization in the treatment of atrial fibrillation (AF) or atrial flutter.The...
|
|
|
Lack of sleep more dangerous for women
Women who get less than the recommended eight hours sleep a night are at higher risk of heart disease and heart-related problems than men with the same sleeping patterns.Research by the University of Warwick and University College London...
|
|
|
Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter
Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg tablets.Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve...
|
|
|
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community
During median follow-up of 12.8 yrs, 418 cardiovascular and 230 coronary events Models with conventional risk factors had C statistics of 0.758 and 0.760 for cardiovascular and coronary events, respectively Biomarkers retained in...
|
|
|
BioSante Pharmaceuticals Research Published in The Journal of Sexual Medicine
(Close-Up Media via COMTEX) -- BPAX | Quote | Chart | News | PowerRating -- BioSante Pharmaceuticals, Inc., which is developing a testosterone gel (LibiGel) to treat hypoactive sexual desire disorder (HSDD) in women, comments on results in a...
|
|
|
Poor sleep may be more dangerous for women than men
Women who get less than the recommended eight hours sleep a night are at higher risk of heart disease and heart-related problems than men with the same sleeping patterns.Research by the University of Warwick and University College London...
|
|
|
Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Dise
ABMS Advises Patients on How to Select a Doctor CHICAGO, July 2 /PRNewswire-USNewswire/ -- Recent news reports have highlighted the importance of physician credentials and ensuring that physicians meet high standards in their chosen area of...
|
